Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...

Stronger-than-expected economic support from consumers reinforces the case for the Federal Reserve to stay in its holding ...

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

Sarepta Therapeutics Inc. is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts ...